Arvinas Competitors and Similar CompaniesClear all
Arvinas's competitors and similar companies include Foghorn Therapeutics, Agenus and Elicio Therapeutics.
 Arvinas Arvinas is a biopharmaceutical company focused on developing protein degradation therapeutics for cancers and other diseases. |  Foghorn Therapeutics Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. |  Agenus Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. |  Elicio Therapeutics Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and hematologic cancers. | |
Founding Date | Founding Date N/A | Founding Date 2016 | Founding Date 1994 | Founding Date 2011 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations New Haven, US HQ | Locations Cambridge, US HQ Cambridge, US | Locations Lexington, US HQ Cambridge, GB Berkeley, US New York, US | Locations Cambridge, US HQ |
Employees | Employees 13329% increase | Employees 16135% increase | Employees 32812% increase | Employees 22 |
Valuation ($) | Valuation ($) 1.2 b | Valuation ($) 179.4 m | Valuation ($) 296.5 m | Valuation ($) 47.2 m |
Twitter followers | Twitter followers 3.1 k | Twitter followers 1.1 k | Twitter followers 2.5 k | Twitter followers N/A |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 13 | Number of tweets (last 30 days) 9 | Number of tweets (last 30 days) 8 | Number of tweets (last 30 days) N/A |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 2 | Average likes per tweet (last 30 days) 2.3 | Average likes per tweet (last 30 days) 13.4 | Average likes per tweet (last 30 days) N/A |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 84.62% | Percentage of tweets with engagement (last 30 days) 88.89% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A |
Employee Rating | Employee Rating 4.7 | Employee Rating 4.2 | Employee Rating 3.2 | Employee Rating 5 |
Financial | ||||
Revenue (est.) | Revenue (est.) $131.4m (FY, 2022) | Revenue (est.) $19.2m (FY, 2022) | Revenue (est.) $98m (FY, 2022) | Revenue (est.) $2.3m (FY, 2022) |
Net income | Net income ($282.5m) (FY, 2022) | Net income ($108.9m) (FY, 2022) | Net income ($230.7m) (FY, 2022) | Net income ($38.8m) (FY, 2022) |
Funding | ||||
Total funding raised | Total funding raised $ 111.6m | Total funding raised $ 50m | Total funding raised $ 171.1m | Total funding raised $ 150.3m |
For sources of this data, please see the company profile
View Company Profiles
Foghorn Therapeutics
HQ
Cambridge, US
Employees
161↑ 35% increase
Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors.
View companyAgenus
HQ
Lexington, US
Employees
328↑ 12% increase
Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer.
View companyElicio Therapeutics
HQ
Cambridge, US
Employees
22
Elicio Therapeutics (formerly known as Vedantra Pharmaceuticals) is an immuno-oncology company developing vaccines and immunotherapies for aggressive solid and hematologic cancers.
View company